From BigGo Finance · BigGo Finance · · 1m 30s
Roche Bets $1.16 Billion on RNAi Weight-Loss Therapy
Roche secures $1.16 billion RNAi weight-loss drug deal with Rona Therapeutics.
In brief
Roche secures $1.16 billion RNAi weight-loss drug deal with Rona Therapeutics. Roche acquired rights to Rona Therapeutics' ALK7 RNAi weight-loss candidate for up to $1.16 billion, targeting visceral fat reduction without muscle loss. Originally reported by BigGo Finance.
Roche and Rona Therapeutics
Roche entered into a global exclusive licensing agreement with Rona Therapeutics valued at up to $1.16 billion.
Upfront and Milestone Payments
Rona Therapeutics receives up to $100 million in upfront payments and up to $1.06 billion in development milestone payments.
ALK7 Target Mechanism
ALK7 acts directly on fat cells to reduce visceral fat while preserving lean body mass.
Complementary to GLP-1 Therapies
ALK7 therapies could improve weight loss quality and durability compared to GLP-1 drugs that cause muscle loss.
Rona's Pipeline
Rona Therapeutics has 15 pipeline programs including obesity, hypertension, and cardiomyopathy treatments.
Competitor Activity
Arrowhead, Alnylam, GSK, and Novo Nordisk are also investing in ALK7 RNAi therapies.
Roche's Weight-Loss Strategy
Roche acquired enicepatide from Carmot Therapeutics for weight loss and has terminated eight clinical assets in 2026.
Market Growth Projections
Global weight-loss drug market expected to reach $54 billion by 2030 with 35% annual growth from 2024.
Clinical Trial Results
Obese patients showed 14.1% visceral fat reduction after eight weeks with single dose of ALK7 RNAi therapy.
Next Steps for ALK7
Rona Therapeutics' ALK7 candidate must pass clinical trials to become a weight-loss treatment.
The bottom line
Roche acquired rights to Rona Therapeutics' ALK7 RNAi weight-loss candidate for up to $1.16 billion, targeting visceral fat reduction without muscle loss.
